Ozempic and Wegovy, known for their physical health benefits, are now being explored for potential applications in addiction treatment, addressing issues like alcohol and opioid dependency. The Caron Treatment Center in Pennsylvania is pioneering the off-label prescription of semaglutide, the active ingredient in these drugs, for addiction recovery. Steven Klein, an addiction specialist at Caron, believes this approach is a valid use of GLP-1s. Despite limited research, evidence is building to support its effectiveness as a treatment for neuropsychological conditions.
Drugs like Ozempic and Wegovy are now showing promise for treating neuropsychological conditions, especially in addiction recovery, demonstrating potential for various addictions, including alcohol and opioids.
Caron Treatment Center is pioneering the use of GLP-1s off-label for addiction treatment, emphasizing semaglutide's role amid a growing body of evidence supporting its therapeutic benefits.
Steven Klein, an addiction specialist at Caron, asserts that using GLP-1s for addiction treatment is not a radical departure from established practices in the field.
The rehabilitation facility features a cadre of leaders, all with personal experience in addiction recovery, who advocate for the innovative use of these medications.
Collection
[
|
...
]